Welltin 16 Tablet contains Betahistine 16 mg as its active ingredient, a histamine analog used primarily in the management of Ménière’s disease and vestibular vertigo. Betahistine acts by improving microcirculation in the inner ear, thereby reducing endolymphatic pressure and alleviating symptoms such as vertigo, tinnitus, and hearing loss associated with vestibular disorders. Welltin 16 is indicated for patients experiencing recurrent episodes of dizziness and imbalance due to inner ear pathology. The medication is administered orally, with the dosage tailored according to the severity of symptoms and patient response. Betahistine’s mechanism involves H1 receptor agonism and H3 receptor antagonism, which enhances histamine turnover and promotes vasodilation in the inner ear vasculature. This results in improved blood flow and reduction of vestibular symptoms. Welltin 16 is generally well tolerated, with adverse effects being rare and typically mild, including gastrointestinal discomfort and headache. It is contraindicated in patients with pheochromocytoma and should be used cautiously in those with asthma or hypersensitivity to the drug. Welltin 16 should be prescribed under medical supervision, with regular monitoring to assess therapeutic efficacy and tolerability.